BELLEVUE, Wash., Nov. 4, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a
biotechnology company specializing in the development of immunotherapeutic
vaccines for cancer and infectious diseases, has signed a license agreement with
Under the license TapImmune may use the proprietary PER.C6(R) cells in its
development programs. The PER.C6(R) cell line is ideally suited for the
development and large-scale manufacturing of a multitude of biopharmaceuticals.
In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do
not generate replication competent adenoviruses, making it the state-of-the-art
platform for the large-scale production of adenoviral vectors for clinical
The PER.C6(R) cell line is the best documented cell line for vaccine development
to date. Its extensive Biologics Master File at the U.S. FDA can be
cross-referenced by licensees, resulting in simplification and acceleration of
the IND filing and approval process.
The partnership between TapImmune and Crucell is important for the production of
TapImmune's vaccine products. Under the terms of this agreement, Crucell has the
rights to negotiate a license for TapImmune's TAP technologies for infectious